WASHINGTON - The Food and Drug Administration has issued enforcement letters to four drug makers for making inaccurate or incomplete statements in drug promotions.
The letter to Eli Lilly cites an ad for the antidepressant Cymbalta. According to the FDA, the ad did not adequately display information about side effects. The company said it is working to remove the materials from marketing circulation.
Cephalon faces similar complaints about missing risk information in promotional cards for Treanda, a lymphoma treatment. A spokeswoman said the company has instructed sales people to stop using the card.
Regulators took issue with statements made by Amylin Pharmaceuticals about its diabetes drug Byetta.
Amylin and partner Lilly said they “will take action as needed.’’
Also, the FDA said Bayer’s script for a presentation on its birth control implant Mirena “overstates the efficacy.’’
The company has ended the promotion.